Cidara Therapeutics Inc's Comment on Sales, Marketing and Customers
Cidara Therapeutics, Inc. develops drug-Fc conjugate immunotherapies using its proprietary Cloudbreak platform for the biotechnology and pharmaceutical markets. Its lead clinical-stage asset, CD388, is intended for influenza prophylaxis. CD388 was developed in partnership with J&J Innovative Medicine, formerly Janssen Pharmaceuticals, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson. Cidara reacquired worldwide rights to develop and commercialize CD388 through a license and technology transfer agreement with Janssen. The company completed a private placement led by RA Capital Management, with participation from Bain Capital Life Sciences, Biotech Value Fund, and Canaan Partners, to fund CD388 development. Additionally, Cidara divested rezafungin, its sole non-Cloudbreak asset, selling it to Napp Pharmaceutical Group Limited, an affiliate of Mundipharma Medical Company, which holds the license for rezafungin outside the U.S. and Japan.
In a significant development within the realm of infectious disease management, Cidara Therapeutics has announced the commencement of its Phase 3 ANCHOR trial, which aims to evaluate the efficacy of CD388 in preventing seasonal influenza among high-risk populations. This important milestone marks the beginning of an ambitious study expected to enroll approximately 6,000 participants across various locations, primarily in the Northern Hemisphere, aligning with the impending influenza season.Influenza remains a persistent public health challenge, posing a considerable risk to vulnerable groups, including the elderly, those with compromised immune systems, and individuals with underlying health conditions. Trad...
Cidara Therapeutics, Inc. has recently announced pivotal steps in its strategic focus on the development of CD388, an innovative drug-Fc conjugate (DFC) candidate aimed at combating influenza A and B. This comprehensive review delves into the data presented at the OPTIONS XII for the Control of Influenza Conference, outlining the safety and pharmacokinetics of CD388. Additionally, the paper explores the implications of Cidara’s workforce restructuring and the significant divestiture of rezafungin, enabling the company to channel efforts and resources into its Cloudbreak® DFC pipeline. The continuous threat posed by influenza viruses necessitates the development of novel therapeutics that offer effective ...
SAN DIEGO, May 30, 2024Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company leveraging its proprietary Cloudbreak® platform to develop innovative drug-Fc conjugate (DFC) immunotherapies, is poised to make a significant contribution at the American Society for Microbiology (ASM) Microbe 2024 conference. The event, scheduled from June 13-17, 2024, at the Georgia World Congress Center in Atlanta, Georgia, will witness the unveiling of preclinical data on Cidara s cutting-edge candidate, CD388. The Groundbreaking Potential of CD388CD388 represents a novel class of DFC immunotherapies under development by Cidara Therapeutics aimed at combating serious viral infections specifically. Utilizing the co...
The Ivy Coast of Wall Street: Cidara Therapeutics Legal Quagmire UnveiledCidara Therapeutics Inc. (NASDAQ: CDTX), a leading bio-pharmaceutical company, finds itself in the middle of a mounting legal storm, as Rosen Law Firm, a preeminent global investor rights law firm, launches a potentially damning investigation into potential securities claims on behalf of the company s shareholders. The inquiry emanates from allegations suggesting that Cidara may have introduced materially deceptive business information to the market, posing a substantial risk to the company s investors. Rosen Law Firm has reinforced its reputation as a tireless advocate for shareholders, consistently riding shotgun for investors right...
Cidara Therapeutics, a renowned biotechnology company, recently unveiled groundbreaking preclinical data on two of its novel drug candidates at the ESMO Immuno-Oncology Annual Congress. The presentations centered around their dual-acting drug-Fc conjugates and a first-in-class CD73/PD-1 inhibitor. Studies on the dual-acting drug-Fc conjugates demonstrated highly promising results, showcasing their potential to revolutionize cancer treatment. In humanized mouse models of colorectal cancer, the conjugates exhibited robust anti-tumor activity, even at low doses. This exciting discovery suggests that Cidara Therapeutics drug-Fc conjugates possess the ability to effectively combat tumors while pote...
In an exciting development for the medical community, Melinta Therapeutics and Cidara Therapeutics have proudly announced the publication of landmark research assessing the efficacy and safety of their innovative drug, REZZAYO (rezafungin for injection), for the treatment of candidemia and invasive candidiasis. The peer-reviewed article, Efficacy and safety of rezafungin and caspofungin in candidemia and invasive candidiasis: pooled data from two prospective randomized controlled trials, provides a comprehensive analysis of the impressive pooled data collected from the Phase 3 Pivotal ReSTORE trial and the Phase 2 STRIVE trial. This breakthrough promises a potential shift in the landscape of fungal...
Cidara Therapeutics, a biotechnology company specializing in the development of innovative therapies for cancer treatment, is set to unveil groundbreaking preclinical data on their novel dual-acting drug-Fc conjugates at the ESMO Immuno-Oncology Annual Congress. This exciting development marks the first-ever presentation of preclinical data on dual CD73/PD-1 targeting DFC, positioning Cidara at the forefront of revolutionary cancer research.
Cidara Therapeutics has continuously demonstrated a commitment to pioneering advancements in cancer treatment, and their latest research on dual-acting drug-Fc conjugates is no exception. The company s innovative approach combines two individual drug t...
Cidara Therapeutics Inc’s Comment on Sales, Marketing and Customers
Cidara Therapeutics, Inc. develops drug-Fc conjugate immunotherapies using its proprietary Cloudbreak platform for the biotechnology and pharmaceutical markets. Its lead clinical-stage asset, CD388, is intended for influenza prophylaxis. CD388 was developed in partnership with J&J Innovative Medicine, formerly Janssen Pharmaceuticals, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson. Cidara reacquired worldwide rights to develop and commercialize CD388 through a license and technology transfer agreement with Janssen. The company completed a private placement led by RA Capital Management, with participation from Bain Capital Life Sciences, Biotech Value Fund, and Canaan Partners, to fund CD388 development. Additionally, Cidara divested rezafungin, its sole non-Cloudbreak asset, selling it to Napp Pharmaceutical Group Limited, an affiliate of Mundipharma Medical Company, which holds the license for rezafungin outside the U.S. and Japan.
Sources:
Cidara Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Cidara Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Cidara Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
